武汉大学肝胆疾病研究院暨武汉大学移植医学中心经武汉大学批准，于2006年由前法国总统希拉克奠基，2007年由时任中国科学院副院长陈竺院士代表中国科学院与武汉大学、法国健康医学研究院携手在武汉大学中南医院正式组建。以肝胆胰脾常见病、多发病和疑难重症为常规医疗项目，以DCD（公民逝世后捐献，Donation after Citizen’s Deceased）器官移植为特种医疗方向，以背驮式肝移植、自体肝移植为特色品牌，多项技术国际、国内领先，现已发展成为集医疗、科研和高层次人才培养为一体的临床治疗和科研中心。叶啟发教授任院长，学科团队为湖北省自然科技基金创新群体，是武汉大学硕、博士点及博士后流动站。
我科围绕关节疾病进行的相关临床与基础研究工作，填补了多项国内、外空白；获得2016年湖北省科技进步一等奖及2017年中华医学科技奖三等奖，主持国家自然科学基金16项（重点项目1项），国家科技研发重大项目子课题3项，湖北省重点研发计划项目1项。相关临床研究成果发表在世界骨科顶级期刊BJJ（原JBJS British Volume）（双1区TOP）和世界运动医学（骨科）顶级期刊《The American Journal of Sports Medicine》和《Arthroscopy》（双1区TOP）。
Department of Hematology, Zhongnan Hospital of Wuhan University
Department of Hematology at Zhongnan Hospital of Wuhan University was established in the 1970s. After decades of development, it now possesses three wards with 105 open beds and 14 laminar flow beds, treating over 15,000 outpatients, 3,000 inpatients. Department of Hematology is equipped with an independent hematology laboratory and has advanced medical technology and equipment. It can carry out various routine and special examinations, including cell morphology/pathology, immunology, cytogenetics, molecular biology, etc, with the ability to detect, collect, isolate and freeze hematopoietic stem/progenitor cells. The scope of diagnosis and treatment includes various hematological diseases such as anemia, bleeding diseases, and hematological malignancies (including leukemia, lymphoma, multiple myeloma, etc.). Recently, novel strategies such as TMI-based conditioning regimen HSCT, Cord blood cell micro-transplantation, Cord blood cell transplantation and Plasma-free plasmapheresis and Double filtration plasmapheresis (DFPP) have been carried out. Meanwhile, multiple clinical trials and technical cooperation of professional alliance with local hospitals have been undertaken, endowing the Department with a reputation in China. The Department is currently being granted as multiple centers: National Key Clinical Specialty Construction Project (Hematology and Oncology), National Construction Project for Improving the Diagnosis and Treatment of Intractable Diseases (hematology oncology), Hematology Base of National Drug Clinical Trial Institution, Standardized Training Base for Chinese Resident Physician in Hematology, Volunteer Stem Cell Collection Base of Chinese Marrow Donor Program, Standardized Operation Training Base of Blood Component Separation and Cell Therapy in Central China, Postdoctoral Station of Hematology of Wuhan University, Transplantation Medical Center (Stem Cell Transplantation) of Wuhan University, Umbilical Cord Blood Stem Cell Transplantation Center, Diagnosis and Treatment Center for MDS/MPN and Chronic Disease Management Center for Multiple Myeloma.
After several generations of efforts, the Department of Hematology in Zhongnan Hospital has formed a discipline echelon with reasonable age structure, educational level and professional title structure. There are currently 21 physicians and 9 technicians in the department, including 2 doctoral instructors, 12 of which with doctoral degrees and 9 with at least 1 year of overseas workstudy experience. The department also has 5 postdoctoral fellows, 10 doctoral students, and 15 master students receiving education in hematology. It undertakes theoretical teaching and clinical teaching for medical undergraduates, masters and doctoral students, while incubating post-doctoral mobile station and authorized points for doctoral and masters degrees. It also undertakes various scientific research funds at various levels, including 1 National Key Project, 11 National Natural Science Foundation, more than 30 funds from Hubei Province, Wuhan City, and Wuhan University, and a number of national-level teaching programs and MOOC teaching projects. Staff of the department have published more than 200 academic papers in domestic and foreign academic journals as first/corresponding authors, several monographs of Renwei Edition as editor-in-chiefco-editors, and obtained several patents. The department has established long-term and stable medical cooperation relations with blood centers and scientific research institutions of many famous hospitals in China and abroad, including the United States, France, Canada and Hong Kong, providing a reliable guarantee for the development of new diagnosis and treatment technologies. In recent years, the scientific research strength of the department has grown tremendously. In 2020, the department’s STEM ranking of Chinese hospitals in terms of scientific and technological value has risen to No.22 among the nation’s other hospitals.
Professor Fuling Zhou, chief and director of the Department of Hematology, has engaged in basic and clinical research on hematological diseases for decades. She is specialized in the research on the pathogenesis and therapeutic targets of acute myeloid leukemia (AML), and has achieved internationally-leading research results, where she originally proposed the antioxidant pathway for the treatment of AML, which has been approved as a national invention patent and widely applied. Professor Zhou, shortlisted in the 2020 National Top 100 Academic Influence of Hematology Experts, has been invited to present at domestic and foreign academic conferences for more than 50 times. Her scientific research results have also been presented internationally such as the American Society of Hematology (ASH) and the European Hematology Conference (EHA). Additionally, she serves as the review committee of the National Natural Science Foundation of China, and has been repeatedly honored, including the 2020 Wuhan University "Medical Take-off Plan" Outstanding Contribution Award. She presided 1 national key project, 4 National Natural Science Foundation projects, 12 provincial and municipal projects with approved funds of over 23 million yuan. In the past five years, she has published more than 80 high-level SCI papers as the firstcorresponding author with highest single SCI impact factor of 41 and highest single citation of 102 times. She has published 5 monographs as the editor-in-chief and acquired 12 national invention patents.
现任学科带头人赵剡，医学博士，教授，主任医师，博士生导师，2003/2005年毕业于法国巴黎第六大学/法国巴黎第五大学。现任武汉大学中南医院副院长兼急救中心主任，并担任教育部高等学校临床医学类专业教学指导委员会委员、中国医师协会急诊医师分会常委、湖北省医学会急诊医学分会主任委员、湖北省急诊医学质量控制中心主任、湖北省急救与复苏临床医学研究中心主任、湖北省急救技能培训中心主任，全国高等学校八年制及“5+3”一体化临床医学专业第四轮规划教材《急诊医学》副主编（人民卫生出版社）、全国高等学校五年制本科临床医学专业第十轮规划教材《急诊与灾难医学》（第4版）副主编、国家卫计委“十三五”英文版规划教材《Emergency Medicine》副主编（人民卫生出版社）、《Emergency and Critical Care Medicine》杂志副主编，《中华急诊医学杂志》编委，法国驻武汉总领事馆医学顾问。
武汉大学中南医院重症医学科成立于1993年，是国内最早建立的重症医学科之一，现有床位数66张，副高及以上职称医护人员15名，国家级人才1名（教育部长江学者）。设有重症医学教研室，是首批国家临床重点专科、重症医学专业硕士和博士学位授予点、博士后流动站、重症医学专科医师及住院医师规范化培训基地，并获批湖北省重症医学临床医学研究中心、湖北省体外生命支持技术医疗质量控制中心和中国医师协会体外生命支持规范化培训基地。近年来在复旦大学全国最佳专科排行榜中位列重症医学专业全国前十和华中地区第一位，连续两年在中国医院科技量值（STEM）重症医学排名前三，五年总科技量值重症医学排名第四。近3年，我科年均收治人数达3000以上，APACHE II ＞15分的患者比例达50%以上，接受机械通气比例达50%以上，好转转出ICU比率达95%以上，累计收治病例覆盖疑难危重病种清单的80%以上。